Literature DB >> 17257497

Binding activity difference of anti-CD20 scFv-Fc fusion protein derived from variable domain exchange.

Shu Sheng Geng1, Jiannan Feng, Yan Li, Yingxun Sun, Xin Gu, Ying Huang, Yugang Wang, Xianjiang Kang, Hong Chang, Beifen Shen.   

Abstract

Two novel engineered antibody fragments binding to antigen CD20 were generated by fusing a murine IgM-type anti-CD20 single-chain Fv fragment (scFv) to the human IgG1 CH2 (i.e., Cgamma2) and CH3 (i.e., Cgamma3) domains with the human IgG1 hinge (i.e. Hgamma). Given the relationship between structure and function of protein, the 3-D structures of the two engineered antibody fragments were modeled using computer-aided homology modeling method. Furthermore, the relationship between 3-D conformation and their binding activity was evaluated theoretically. Due to the change of active pocket formed by CDRs, the HL23 (VH-Linker-VL-Hgamma-Cgamma2-Cgamma3) remained its activity because of its preserved conformation, while the binding activity of the LH23 (VL-Linker-VH-Hgamma-Cgamma2-Cgamma3) was impaired severely. Experimental studies by flow cytometry and fluorescence microscopy showed that HL23 possessed significantly superior binding activity to CD20-expressing target cells than LH23. That is to say, the order of variable regions could influence the binding activity of the fusion protein to CD20+ cell lines, which was in accordance with the theoretical results. The study highlights the potential relationship between the antibody binding activity and their 3-D conformation, which appears to be worthwhile in providing direction for future antibody design of recombinant antibody.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17257497

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  5 in total

1.  Anti-CHMP5 single chain variable fragment antibody retrovirus infection induces programmed cell death of AML leukemic cells in vitro.

Authors:  Hai-rong Wang; Zhen-yu Xiao; Miao Chen; Fei-long Wang; Jia Liu; Hua Zhong; Ji-hua Zhong; Ren-rong Ou-Yang; Yan-lin Shen; Shu-ming Pan
Journal:  Acta Pharmacol Sin       Date:  2012-05-21       Impact factor: 6.150

2.  Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc.

Authors:  Fabian Richter; Oliver Seifert; Andreas Herrmann; Klaus Pfizenmaier; Roland E Kontermann
Journal:  MAbs       Date:  2019-03-31       Impact factor: 5.857

3.  Bioinformatics-led design of single-chain antibody molecules targeting DNA sequences for retinoblastoma.

Authors:  Guo-Gang Shang; Jian-Hua Zhang; Yong-Gang Lü; Jun Yun
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

4.  Analysis of the relationship between end-to-end distance and activity of single-chain antibody against colorectal carcinoma.

Authors:  Jianhua Zhang; Shanhong Liu; Zhigang Shang; Li Shi; Jun Yun
Journal:  Theor Biol Med Model       Date:  2012-08-22       Impact factor: 2.432

Review 5.  Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis.

Authors:  Damian Maseda; Rachel H Bonami; Leslie J Crofford
Journal:  Expert Rev Clin Immunol       Date:  2014-04-16       Impact factor: 4.473

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.